Colorectal cancer (CRC) is the second most common cause of cancer in women, and the third most common in men and the fourth leading cause of cancer deaths worldwide ([@bib19]). Owning to the development and use of several cytotoxic drugs and molecularly target agents, overall survival in metastatic CRC patients has significantly improved over the last decade.

The therapeutic use of anti-epidermal growth factor receptor (EGFR) monoclonal antibodies is approved in metastatic CRC, with mutation of *KRAS* exon2 being recognised as a strong predictive factor for no clinical benefit of anti-EGFR antibody treatment ([@bib21]; [@bib38]; [@bib11]). Anti-EGFR antibodies comprised cetuximab and panitumumab, and these drugs were confirmed to provide similar outcome improvements and adverse events as determined in a randomised phase III trial ([@bib31]). Recently, genetic analyses of prospective trials indicated that *RAS* mutation, which consists of *KRAS* (exon 2, 3 and 4) and *NRAS* (exon 2, 3 and 4) mutations, is a newly identified predictive biomarker for no clinical benefit of anti-EGFR antibody treatment in metastatic CRC ([@bib10]; [@bib40]). Taking into account key factors involved in the EGFR downstream signalling pathway, *BRAF* V600E mutation was previously reported as a prognostic factor in anti-EGFR antibody treatment of patients with metastatic CRC ([@bib39]). Moreover, the PTEN/PI3K/AKT axis is an important EGFR downstream signalling pathway regulating multiple biological processes such as apoptosis, metabolism, cell proliferation and cell growth ([@bib6]). The loss of PTEN expression was previously reported as a poor prognostic factor in respect to treatment with anti-EGFR antibodies in patients with metastatic CRC ([@bib27]).

Further biomarker analyses in relation to anti-EGFR antibody response in metastatic CRC beyond *RAS* mutation has been performed. In several reports, high expression of epiregulin (EREG) and amphiregulin (AREG) in tumour tissues was associated with better outcome following treatment with cetuximab in metastatic CRC patients ([@bib23]; [@bib18]; [@bib20]). In addition, there have been a few previous reports to evaluate the prognostic value of *ERBB2*, *VEGFA* and *MET* expression in chemotherapy-refractory metastatic CRC patients who were treated with anti-EGFR antibodies. ERBB2 (HER2) is known as a member of the ErbB family of receptor tyrosine kinases. HER2 status in tumour tissue an important determinant of whether HER2-targeted agents should be used in patients with breast cancer and gastric or gastro-oesophageal junction adenocarcinoma ([@bib34]; [@bib2]). The hepatocyte growth factor/scatter factor (HGF/SF) and MET receptor signalling pathway elicits multiple cellular responses regulating cell survival, morphogenesis, adhesion, migration, breakdown of extracellular matrix and angiogenesis ([@bib5]; [@bib25]). Vascular endothelial growth factor-A (VEGFA) has a key role in tumour angiogenesis and is a molecular target of anti-VEGF antibodies such as bevacizumab, which is used as first- or second-line treatment for metastatic CRC patients ([@bib16]; [@bib32]). On the other hand, the role of VEGFA as a biomarker of anti-EGFR antibody treatment in metastatic CRC patients is unclear.

There are no established predictive or prognostic markers for use in clinical practice beyond *RAS* or *BRAF* mutations in respect to the treatment with anti-EGFR antibodies in metastatic CRC. In the present study, we selected several genes encoding receptor tyrosine kinases (RTKs), ligands and EGFR downstream molecules as candidate biomarkers of resistance to anti-EGFR antibody use or therapeutic targets of dual-target therapy with anti-EGFR antibody treatment in *RAS* wild-type patients. We analysed the relative mRNA values of each of these genes by using tumour (T) and non-tumour (NT) tissues sections from the same patient, that is, T/NT ratio, to determine the prognostic value of expression of these genes with respect to treatment of metastatic CRC patients with anti-EGFR antibodies.

Materials and methods
=====================

Patients and sample collection
------------------------------

We collected 108 cases of formalin-fixed paraffin-embedded (FFPE) tumour samples from metastatic CRC patients who were treated with anti-EGFR antibodies for genetic analyses. We enrolled 96 *KRAS* exon2 wild-type patients who met the following inclusion criteria: pathologically proven adenocarcinoma, metastatic or recurrent colorectal cancer, an Eastern Cooperative Oncology Group (ECOG) Performance status (PS) of 0 to 2, patients who had previously received one or more standard regimens of systemic chemotherapy, adequate amount of tissue samples for quantitative real-time PCR (qRT--PCR) analyses, no significant abnormality in terms of liver and renal function, patients who received a combination of irinotecan and anti-EGFR antibodies or monotherapy with anti-EGFR antibodies. The main exclusion criteria included the following: previous chemotherapy targeting the EGF pathway, other duplicated advanced cancer and metastasis to the central nervous system. Patients continued to receive chemotherapy until disease progression or intolerable toxicity from chemotherapy intervened. The response was evaluated by contrast-enhanced computed tomography every 2 to 3 months. Patient consent for the use of clinical materials was obtained, and this study was undertaken after approval by the National Cancer Center Institutional Review Board.

Extraction of RNA and qRT--PCR analysis
---------------------------------------

Total RNA (included miRNA) was extracted from T and NT tissue section in same FFPE slides using the miRNeasy FFPE Kit (QIAGEN KK, Tokyo, Japan). The extracted RNA was stocked at −80 °C until use. cDNA was synthesised using PrimeScriptRT MasterMix (Perfect Real Time, Takara Bio Inc., Otsu, Japan). Quantitative real-time PCR was performed in a Thermal Cycler Dice Real-time System TP800 (Takara Bio Inc., Otsu, Japan) using SYBR Premix Ex Taq II (Tli RNaseH Plus, Takara Bio Inc., Otsu, Japan). Quantitative real-time PCR (forward and reverse) used Perfect Real Time Primer (Takara Bio Inc., Otsu, Japan). The primers used for qRT--PCR are summarised in [Supplementary Material 1](#sup1){ref-type="supplementary-material"}. Relative mRNA values as T/NT ratio of target genes in same tissues were calculated to evaluate how level of mRNA expression of T sections were higher compared with that of NT section in each patient. Glyceraldehyde 3-phosphate dehydrogenase (*GAPDH*) was used as a reference gene to correct for differences in terms of both quality and quantity between samples. The relative quantity of *AREG*, *EREG*, *ERBB2*, *MET*, *VEGFA*, *PTEN* and *ERCC1* mRNA in both T and NT sections was normalised to the level of the internal control *GAPDH* mRNA and were expressed as 'tumour ddCt Rel Qty/non-tumour ddCt Rel Qty\' where dCt is the difference between the gene of the target and the *GAPDH* gene, and ddCT is the difference between the dCT for each sample and the control group.

Direct sequencing of *KRAS*, *BRAF*, *PIK3CA* and *NRAS*
--------------------------------------------------------

DNA samples were extracted from FFPE tumour tissue sections. Tumour cell-rich areas within H&E-stained sections were marked under a microscope, and tissue was scraped from the corresponding areas of additional deparaffinised unstained sections. DNA from the scraped-off tissue sample was isolated using the QIAamp DNA FFPE Tissue Kit (QIAGEN KK, Tokyo, Japan). Exon 2 (codons 12 and 13), exon 3 (codon 61), exon 4 (codon 146) of the *KRAS* gene and exon 15 (codon 600) of the *BRAF* gene and exon 9 (codons 542 and 545), exon 20 (codon 1047) of the *PIK3CA* gene and exon 2 (codons 12 and 13), exon 3 (codon 61) of the *NRAS* gene were amplified by PCR (the GeneAmp PCR System 9700 thermal cycler (Life Technologies Japan (Applied Biosystems), Tokyo, Japan)). The methods utilised for genetic analyses of *KRAS, NRAS, BRAF* and *PIK3CA* were as described previously ([@bib35]).

Assessment and statistical analysis
-----------------------------------

To assess associations of relative gene expression levels with the objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS) and overall survival (OS), the values for each gene were categorised into low and high levels with respect to the several cut-off values. Assessment of therapeutic response consisted of complete response (CR), partial response (PR), stable disease (SD), disease progression (PD), and not evaluated (NE), according to the Response Evaluation Criteria in Solid Tumours (RECIST) ver. 1.1. ORR was defined as the proportion of patients whose best response was a CR or PR among all patients. OS was defined as the interval from initiation of anti-EGFR therapy to death or last follow-up.

Differences in the distribution of variables were evaluated using Fisher\'s exact test or *χ*^2^-test, as appropriate. Progression-free survival and OS were estimated by the Kaplan--Meier method and survival curves were compared by the log-rank test. We estimated hazard ratios (HRs) and the corresponding 95% confidence intervals (CIs) for PFS and OS using univariate and multivariate analysis by Cox proportional hazards model. Relevant clinicopathological variables included age (⩽60 *vs* \>60), gender (male *vs* female), ECOG PS (0--1 *vs* 2), histological type (differentiated *vs* undifferentiated), primary site (colon *vs* rectum), stage (stage IV *vs* recurrence), number of metastatic sites (1 *vs* 2 or more), resection of primary site (yes *vs* no), metastatic sites (liver metastasis and peritoneal dissemination), anti-EGFR antibody (cetuximab *vs* panitumumab), treatment (combination *vs* monotherapy), minor *KRAS*/*NRAS* mutations (yes *vs* no). Adjusted HRs for *ERBB2*, *MET*, *VEGFA*, *PTEN*, *ERCC1*, *EREG* and *AREG* gene expression levels were determined according to age, gender, performance status, minor *RAS* mutations and other clinicopathological variables, which displayed *P*-values \<0.1 from the univariate analysis. Receiver operating characteristics curve analysis was performed to determine the optimal cutoff values for each gene as continuous variables. All tests were two-sided and a *P*-value \<0.05 was defined as statistically significant. We performed statistical analyses via use of SPSS statistical software, version 19 (IBM, Tokyo, Japan).

Results
=======

Among 108 patients who were treated with anti-EGFR antibodies, a total of 96 *KRAS* exon 2 wild-type patients met the selection criteria between August 2008 and August 2011 in our institution. The patient characteristics of this cohort are summarised in [Table 1](#tbl1){ref-type="table"}. The median age was 61 years old, and the histological tumour types comprised differentiated (89.6%) and undifferentiated (10.4%) adenocarcinoma. Most patients (96.9%) underwent prior resection of the primary site. Seventy patients (80.2%) were treated with irinotecan-based chemotherapy plus anti-EGFR antibody and others (19.8%) were treated with anti-EGFR antibody monotherapy. Thirty-two patients (31.1%) received subsequent treatment after failure of anti-EGFR antibodies. With respect to occurrence of minor *KRAS* and *NRAS* alternations, gene mutations in *KRAS* codon 61 (*n*=2), *KRAS* codon 146 (*n*=2), *NRAS* codon 13 (*n*=3) and *NRAS* codon 61 (*n*=2) were detected. In addition, *BRAF* V600E mutation was detected in two patients.

Distribution of relative mRNA levels for each gene of interest
--------------------------------------------------------------

The relative mRNA values for each gene of interest are shown in [Table 2](#tbl2){ref-type="table"}. Median values of ERBB2 (*n*=58), MET (*n*=60), PTEN (*n*=65), VEGFA (*n*=78), ERCC1 (*n*=80) and EREG (*n*=60) were 0.62 (measurable range: 0.0011--32.228), 0.905 (0.030--568.165), 0.688 (0.0040--17.875), 0.69 (0.00031--33.823), 0.486 (0.0015--75.059) and 0.408 (0.00025--216.747), respectively. The respective mRNA levels of each gene in both T and NT sections are summarised in [Supplementary Material 2](#sup1){ref-type="supplementary-material"}. The relative mRNA value of AREG could not be calculated in most cases as the expression of this gene generally undetectable in NT sections. Accordingly, the prognostic role of AREG expression was evaluated by utilising the data from tumour tissue sections alone.

The distribution of relative mRNA values for each gene of interest is shown in [Figure 1](#fig1){ref-type="fig"}. When 4 quartiles were generated based on relative mRNA values for particular genes, the mRNA values for these genes were significantly elevated in the upper 25% quadrant.

Prognostic analyses of patient\'s characteristics and relative mRNA values of target genes in relation to PFS and OS
--------------------------------------------------------------------------------------------------------------------

The results of prognostic analyses assessing various patient characteristics are shown in [Table 3](#tbl3){ref-type="table"}. ECOG-PS 2 (HR 3.035, 95% CI: 1.502--6.130, *P*=0.002), peritoneal dissemination (HR 1.717, 95% CI: 1.008--2.927, *P*=0.046), treatment (HR 0.388, 95% CI: 0.244--0.672, *P*=0.001) and minor *KRAS/NRAS* mutation (HR: 0.390, 95% CI: 0.205--0.733, *P*=0.004) were identified as prognostic factors of PFS by univariate analyses. In addition, prognostic factors relevant to OS were determined as ECOG-PS 2 (HR 4.805, 95% CI: 2.121--10.887, *P*\<0.001), peritoneal dissemination (HR 1.966, 95% CI: 1.070--3.613, *P*=0.029), and treatment (HR 0.352, 95% CI: 0.190--0.652, *P*=0.001).

In order to investigate the optimal cutoff levels of relative mRNA values, adjusted HRs of target genes were calculated according to the 25th, 50th (median) and 75th percentile of relative mRNA value of each gene. When the cutoff level of each gene was determined as the 25th percentile of relative mRNA values, there was no difference in terms of PFS and OS for any of the target genes assessed. Although high relative mRNA values for MET were associated with shorter PFS compared with low MET when the cutoff values were median, relative mRNA values of the other genes were not associated with prognosis when this particular cutoff value was utilised. The results of prognostic analyses of each gene at the 75th percentile are summarised in [Table 4](#tbl4){ref-type="table"}. The cutoff value of each gene at 75th percentile were 1.933 (*EREG*), 1.742 (*ERBB2*), 2.346 (*MET*), 2.298 (*VEGF-A*), 1.841 (*PTEN*) and 1.505 (*ERCC1*), respectively. HRs of each gene were adjusted according to age, gender, ECOG-PS and other clinicopathological variables, which exhibited *P*-values\<0.1 on the basis of univariate analysis. Among the target genes assessed, prognostic factors were high level of EREG (HR: 0.326, 95% CI: 0.136--0.772, *P*=0.011), ERBB2 (HR: 1.31, 95% CI: 1.084--1.652, *P*=0.040), MET (HR: 2.48, 95% CI: 1.356--5.463, *P*=0.026), and VEGF-A (HR: 1.29, 95% CI: 1.036--1.606, *P*=0.046). Patients with high *ERBB2* had shorter PFS compared with those with low *ERBB2* (HR: 1.98, 95% CI: 1.062--3.850, *P*=0.042). There were no significant differences in PFS and OS in relation to *ERCC1* and *PTEN*. High expression of *AREG* in tumour section was associated with shorter OS compared with low AREG (HR: 0.277, 95% CI: 0.095--0.808, *P*=0.019).

There was no significant difference with regards to the frequency of subsequent treatment between subgroups of low and high relative mRNA values of *ERBB2* (33.3% *vs* 35.7%), *MET* (34.9% *vs* 33.3%), *VEGFA* (37.3% *vs* 31.6%), *EREG* (35.7% *vs* 34.1%), *ERCC1* (33.3% *vs* 36.8%), *PTEN* (27.1% *vs* 29.4%) and *AREG* (40.0% *vs* 46.7%).

Survival curves and response according to relative mRNA levels of target genes
------------------------------------------------------------------------------

Survival curves of PFS and OS according to relative mRNA values of *ERBB2*, *MET* and *VEGFA* (cutoff level: 75th percentile of all patients) in *KRAS* wild-type patients are shown in [Figure 2](#fig2){ref-type="fig"}. High relative mRNA value of ERRB2 was associated with shorter PFS and OS compared with low *ERBB2* (median PFS: 4.1 months *vs* 9.0 months, *P*=0.032; median OS: 8.2 months *vs* 17.1 months, *P*=0.043; log-rank test, respectively). There were significant differences in PFS between high and low levels of *MET* and *VEGFA* mRNA. On the other hand, high relative mRNA value of *MET* was associated with shorter OS compared with low *MET* (9.8 months *vs* 17.3 months, *P*=0.038). There was no significant difference statistically, but high relative mRNA value of *VEGFA* had a tendency to be associated with shorter OS compared with low *VEGFA* (9.8 months *vs* 14.3 months, *P*=0.062). There were no significant differences in either PFS or OS when relative mRNA expression values of *ERCC1* and *PTEN* were considered.

Results relating to links between ORR and relative mRNA values of target genes is provided in [Supplementary Material 3](#sup1){ref-type="supplementary-material"}. There were no significant differences in ORR when relative mRNA values of target genes were evaluated, but patients having a low relative mRNA value for *ERBB2* (13.3% *vs* 25.6%) and *EREG* (25.0% *vs* 20.5%) tended to do better than those that did not.

Discussion
==========

According to previous reports, expression of *EREG* and *AREG* in tumour tissues are recognised as biomarkers to predict the outcome of anti-EGFR antibody treatment in *KRAS* wild-type patients ([@bib21]; [@bib38]; [@bib11]). In addition to *EREG* and *AREG*, our study investigated the prognostic role of *ERBB2*, *MET*, *VEGFA*, *PTEN* and *ERCC1* mRNA expression in tumour *vs* normal tissue within the same patient, that is T/NT ratio, in a cohort of metastatic CRC patients. High relative mRNA values of *ERBB2*, *MET* and *VEGFA* were associated with worse OS compared with low levels of these genes. These findings indicated the possibility that overexpression of these genes are associated with inherent or acquired resistance to anti-EGFR antibody treatment. Accordingly, inhibitors of such genes may improve the outcome of anti-EGFR antibody treatment in *RAS* wild-type patients with metastatic CRC. To our knowledge, although this is a study that evaluated several candidate prognostic/predictive biomarkers via qRT--PCR in patients who received first-line chemotherapy with or without cetuximab ([@bib9]), there are no comparable studies in patients of chemotherapy-refractory metastatic CRC patients treated with anti-EGFR antibodies.

The *ERBB2* (*HER2*) gene encodes a member of the EGFR family of receptor tyrosine kinases and is located at the long arm of human chromosome 17. In relation to CRC, preclinical research utilising xenopatient models indicated that HER2 amplification is observed specifically in a subset of tumours resistant to cetuximab and exhibiting wild-type *KRAS/NRAS/BRAF/PIK3CA* (quadruple negative); moreover, analysis of HER2-amplified xenopatients revealed that combination of HER2 and EGFR inhibitors induced long-lasting tumour regression ([@bib4]). In this study, HER2 amplification occurs in, respectively, 3% of metastatic CRC patients, 14% of *KRAS* wild-type patients and possibly up to 30% of quadruple negative patients resistant to EGFR-targeted antibodies. In addition, amplification of ERBB2 and ERBB2/ERBB3 signalling promote downstream signalling such as the Akt pathway in cetuximab-resistant CRC cells; in addition, addition of either HER2 or HER3 inhibitors with anti-EGFR antibodies in equivalent xenograft models resulted in tumour regression ([@bib43]; [@bib44]). These preclinical data support our results and the concept that amplification of the *ERBB2* gene confers primary resistance to anti-EGFR antibody treatment, making it a promising target for *RAS*/*BRAF* wild-type patients treated with anti-EGFR antibodies. However, the optimal target-population that could obtain clinical benefit from HER2 inhibitors is not s far established by large-scale clinical trials involving CRC patients. In our study, overexpression of the *ERBB2* gene in T *vs* NT tissue sections was detected in a subgroup within the upper 25th percentile of relative mRNA values, with this subgroup being associated with worse PFS and OS following treatment with anti-EGFR antibodies. According to previous reports of retrospectively assessed specimens, the frequency of HER2 positivity in CRC as evaluated by overexpression of HER2 protein and amplification of *ERBB2* has been reported to range from 2.7 to 47.7% ([@bib30]; [@bib28]; [@bib12]; [@bib8]). A recent large-scale cohort study of HER2/neu testing in CRC, utilising the same scoring system as that used in expert guidelines for breast cancer and gastric cancer, showed HER2/neu positivity rate to be 1.6% ([@bib15]; [@bib42]; [@bib17]). Potential reasons of these apparent discrepancies in relation to HER2 positivity rates in CRC include study-specific differences in definition of HER2 positivity, sample size, methodological approach and tissues samples utilised. The HERACRES-A trial, a recent phase II study to evaluate the efficacy and safety profile of combination of trastuzumab and lapatinib in HER2-amplified metastatic CRC patients, revealed that enrolled patients achieved high ORR (34.7%) and disease control rate (78.3%) ([@bib33]). In spite of the promising outcome and tolerability profile, the frequency of HER2 amplification observed was only 5.4%, even though this trial included patients with HER2 IHC2+ and IHC3+ tumours. In addition, half of the HER2-amplified patients could not receive treatment with HER2-targeted therapeutics due to poor prognosis and tumour complications after failure of standard chemotherapy. Going forward, definition of an optimal cut-off value and methodological approach for determination HER2 amplification, along with adequate treatment regimens incorporating HER2 inhibitors, is required for the appropriate development of clinical trials in HER2-amplified patients with metastatic CRC.

In the present study, a high level of *MET* mRNA expression was associated with shorter survival, whereas there is no significant association between expression of this gene and response to anti-EGFR therapy. This may indicate that overexpression of the *MET* gene is not relevant for primary resistance to anti-EGFR antibody treatment, but it may be linked to acquired resistance to anti-EGFR antibody usage in metastatic CRC patients. With respect to resistance mechanisms relating to anti-EGFR antibody treatment, previous reports indicated that ligand-dependent MET activation contributes to cetuximab resistance in colon cancer ([@bib26]; [@bib36]). [@bib3] reported that amplification of the MET locus was detected in circulating tumour DNA before relapse from treatment with anti-EGFR antibody was clinically confirmed. Other than *MET* expression, co-expression of the *MET* gene and HGF is associated with advanced stage and poor survival in CRC ([@bib22]). In addition, we previously described that a high level of serum HGF was associated with worse outcome following anti-EGFR antibody treatment in *KRAS* wild-type patients ([@bib35]). It seems that the addition of HGF can further trigger MET-initiated signalling and cause resistance to anti-EGFR antibody treatment. Actually, combination of panitumumab and anti-HGF antibody (rilotumumab) induced better response compared with panitumumab monotherapy in *KRAS* wild-type patients in a recent phase Ib/II trial ([@bib37]). Further investigation of biomarkers within the HGF/MET pathway, including downstream factors, is needed to aid the development of molecularly targeted drugs relevant to this pathway in CRC.

VEGFA is a major ligand against VEGF receptor and causes the angiogenesis of tumour tissues, as well as enhancing tumour invasion and distal metastasis. Our study indicated that patients with VEGFA-amplified tumours had shorter OS compared with those without VEGFA-amplified tumours. In preclinical studies, increased VEGF expression in CRC tumour cells has a role in the development of anti-EGFR therapy resistance ([@bib41]; [@bib13]). In addition, chronic administration of EGFR inhibitors to mice with colon cancer xenografts induced resistant cells with increased VEGF expression; notably, VEGF receptor-targeting tyrosine kinase inhibitors achieved anti-tumour activity against those xenografts exhibiting resistance to EGFR inhibitor ([@bib7]). In a recent phase II trial, combination of TAS-102 and bevacizumab showed both a good efficacy and safety profile in metastatic CRC patients after failure of standard therapies including anti-EGFR antibody and anti-VEGF antibody usage ([@bib24]). It is possible that patients with VEGF-amplified tumours may comprise a particular subgroup that obtains clinical benefit from a strategy employing bevacizumab beyond progression (BBP) or rechallenge of chemotherapy with anti-VEGF antibodies.

There are some limitations to the present study. First, this study is retrospective in nature and patients without adequate tissue samples for qRT--PCR analysis were excluded, which may cause a potential selection bias. Further validation of our findings via other translational research studies, including those of prospective nature, are required. Second, there were several cases that exhibited no amplification of target genes by qRT--PCR analysis. One of the contributory reasons may be inadequate quality control of tumour tissue samples, such as discrepancies in relation to time utilised for formalin fixation between cases. In addition, *AREG* gene expression in certain contexts, for example, normal tissues, were lower compared with the expression of other target genes in present study. To address this, a digital PCR system may be better method to facilitate absolute quantification of infrequent or lowly expressed genes in tumour tissues. This system has many potential advantages such as the capability to obtain absolute quantification without external references and robustness to variations in PCR efficiency ([@bib1]). Third, survival time after failure of anti-EGFR antibody in present study may be affected by the recent approved drugs such as regorafenib or TAS102 as salvage-line chemotherapy ([@bib14]; [@bib29]). There is no significant difference between high and low levels of relative mRNA value of each gene in the frequency of subsequent treatment after failure of anti-EGFR antibody, but five patients received these drugs and might tend to achieve long survival in present study.

In conclusion, overexpression of *ERBB2*, *MET* and *VEGFA* genes as the T/NT ratio of mRNA level of each gene in tumour tissues were associated with worse prognosis on the treatment of anti-EGFR antibody in metastatic CRC patients. As development of precision medicine, our findings may contribute the novel strategy of combination or sequential use of molecular target drugs of these genes on the treatment of anti-EGFR antibody in *RAS* wild-type patients. In addition, further research of optimal predictive markers of these genes and validation study are also required in the future.
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![**Relative value of mRNA expression of target genes.** Relative mRNA values of target genes were expressed as 'tumour ddCt Rel Qty/non-tumour ddCt Rel Qty\' where dCt is the difference between the gene of the target and the GAPDH gene, and ddCT is the difference between the dCT for each sample and the control group.](bjc201674f1){#fig1}

![Survival curves of progression-free survival and overall survival according to relative mRNA values (high/low) of *ERBB2*, *MET* and *VEGFA* in *KRAS* wild-type patients who were treated with anti-EGFR antibodies. MST (Median survival time) - median overall survival.](bjc201674f2){#fig2}

###### Patients\' characteristics

                                                 **Total**
  ------------------------------------------- ---------------
  Number of patients                                96
  Median age (range)                           61.0 (32--83)
  **Gender (%)**                              
  Male                                           68 (70.8)
  Female                                         28 (29.2)
  **ECOG PS (%)**                             
  0--1                                           85 (88.5)
  2                                              11 (11.5)
  **Primary site (%)**                        
  Colon                                          42 (79.1)
  Rectum                                         54 (20.9)
  **Histological type (%)**                   
  Well, mod, pap (differentiated)                86 (89.6)
  Por, sig, muc (undifferentieted)               10 (10.4)
  **Stage (%)**                               
  Stage IV                                       40 (41.7)
  Reccurence                                     56 (58.3)
  **Prior resection of primary lesion (%)**   
  Yes                                            93 (96.9)
  No                                              3 (3.1)
  **Number of metastatic site (%)**           
  1                                              30 (31.3)
  ⩽2                                             66 (68.7)
  **Liver metastasis (%)**                    
  Yes                                            64 (66.7)
  No                                             32 (33.3)
  **Peritoneal dissemination (%)**            
  Yes                                            20 (20.8)
  No                                             76 (79.2)
  **Treatment lines (%)**                     
  Second-line                                     6 (6.3)
  Third-line                                     68 (70.8)
  ⩽4th line                                      22 (22.9)
  **Regimens of chemotherapy (%)**            
  Combination with irinotecan                    77 (80.2)
  Monotherapy                                    19 (19.8)
  **Anti-EGFR antibody (%)**                  
  Cetuximab                                      71 (74.0)
  Panitumumab                                    25 (26.0)
  **Subsequent treatment (%)**                
  Yes                                            32 (33.3)
  No                                             64 (66.7)

Abbreviaions: ECOG=Eastern Cooperative Oncology Group; mod=moderately differentiated adenocarcinoma; muc=mucinous adenocarcinoma; PS=Performance status; por=poorly differentiated adenocarcinoma; sig=signet ring cell carcinoma; well=well-differentiated adenocarcinoma.

###### Results of relative mRNA values as tumour and non-tumour ratio in patients who were treated with anti-EGFR antibodies

              **ERBB2**         **MET**          **PTEN**         **VEGFA**        **ERCC1**          **EREG**       **AREG**[a](#t2-fn2){ref-type="fn"}
  -------- ---------------- ---------------- ---------------- ----------------- ---------------- ------------------ -------------------------------------
  Median        0.620            0.905            0.688             0.690            0.486             0.408                        42.25
  Range     0.0011--32.228   0.030--568.165   0.0040--17.875   0.00031--33.823   0.0015--75.059   0.00025--216.747              0.418--3.083

Abbreviations: AREG=amphiregulin; EREG=epiregulin.

mRNA values of AREG in tumour section are shown because mRNA values of AREG in non-tumour sections were below lower limit of measurable range in most cases.

###### Prognostic factors of PFS and OS by univariate analyses in terms of patients\' characteristics

                                   **PFS**  **OS**                                         
  ------------------------------- --------- -------------- ------- ------- --------------- ---------
  **ECOG PS**                                                                              
  0--1                                1                               1                         
  2                                 3.035   1.502--6.130    0.002   4.805  2.121--10.887    \<0.001
  **Gender**                                                                               
  Male                                1                               1                         
  Female                            1.095   0.692--1.731    0.698   1.337  0.753--2.374      0.332
  **Age**                                                                                  
  ⩽60                                 1                               1                         
  \>60                              0.983   0.648--1.490    0.934   0.992  0.557--1.524      0.751
  **Stage**                                                                                
  Stage IV                            1                               1                         
  Recurrence                        1.020   0.669--1.555    0.927   1.023  0.614--1.704      0.929
  **Primary site**                                                                         
  Colon                               1                               1                         
  Rectum                            1.057   0.695--1.607    0.702   0.846  0.514--1.393      0.511
  **Histological type**                                                                    
  Well/mod                            1                               1                         
  Por/sig/muc                       1.634   0.842--3.172    0.147   1.808  0.851--3.840      0.123
  **Metastatic site**                                                                      
  1                                   1                               1                         
  2 or more                         1.041   0.676--1.603    0.856   1.123  0.653--1.931      0.675
  **Liver metastasis**                                                                     
  No                                  1                               1                         
  Yes                               0.908   0.416--0.917    0.908   0.914  0.539--1.552      0.740
  **Peritoneal lesion**                                                                    
  No                                  1                               1                         
  Yes                               1.717   1.008--2.927    0.046   1.966  1.070--3.613      0.029
  **Resection of primary site**                                                            
  No                                  1                               1                         
  Yes                               0.526   0.165--1.677    0.797   0.349  0.108--1.127      0.078
  **Anti-EGFR antibody**                                                                   
  Cetuximab                           1                               1                         
  Panitumumab                       1.011   0.628--1.627    0.965   0.867  0.689--1.532      0.456
  **Treatment**                                                                            
  Monotherapy                         1                               1                         
  Combination                       0.388   0.244--0.672    0.001   0.352  0.190--0.652      0.001
  **Minor KRAS/NRAS mutation**                                                             
  Yes                                 1                               1                         
  No                                0.390   0.205--0.733    0.004   0.468  0.218--1.003      0.051

Abbreviations: CI=confidence interval; ECOG PS=Eastern Cooperative Oncology Group Performance Status; HR=hazard ratio; mod=moderately differentiated adenocarcinoma; muc=mucinous adenocarcinoma; OS=overall survival; PFS=progression-free survival; por=poorly differentiated adenocarcinoma; sig=signet ring cell carcinoma; well=well-differentiated adenocarcinoma.

###### Multivariate analyses of target genes in terms of PFS and OS when cutoff values were determined as 75th percentile of relative mRNA values of each gene

                                            **PFS**   **OS**                                                
  --------------------------------------- ----------- -------------- ----------- ----------- -------------- -----------
  **ERBB2**                                                                                                 
  Low                                          1                                      1                           
  High                                     **1.949**  1.062--3.850    **0.046**   **1.510**  1.084--1.952    **0.040**
  **MET**                                                                                                   
  Low                                          1                                      1                           
  High                                       1.120    0.669--1.555      0.927     **2.482**  1.356--5.463    **0.026**
  **VEGFA**                                                                                                 
  Low                                          1                                      1                           
  High                                       1.057    0.695--1.607      0.702     **1.296**  1.036--1.606    **0.046**
  **PTEN**                                                                                                  
  Low                                          1                                      1                           
  High                                       0.864    0.688--1.087      0.213       0.962    0.727--1.271      0.783
  **ERCC1**                                                                                                 
  Low                                          1                                      1                           
  High                                       0.975    0.806--1.180      0.797       1.047    0.818--1.340      0.717
  **EREG**                                                                                                  
  Low                                          1                                      1                           
  High                                       0.891    0.698--1.138      0.355     **0.326**  0.138--0.772    **0.011**
  **(AREG)**[a](#t4-fn3){ref-type="fn"}                                                                     
  Low                                          1                                      1                           
  High                                       0.459    0.192--1.097      0.080     **0.277**  0.095--0.808    **0.019**

Abbreviations: CI=confidence interval; HR=hazard ratio; mRNA, messenger RNA; PFS=progression-free survival; OS=overall survival.

HRs of biomarkers were adjusted by variables of age (cut-off: 60 years old); gender (male *vs* female); ECOG-PS (0--1 *vs* 2); peritoneal lesion (no *vs* yes); resection of primary site (no *vs* yes); treatment of anti-EGFR antibody (combination *vs* monotherapy); minor *KRAS/NRAS* (mutant *vs* wild). Bold numbers mean the HRs and *P*-values with significant difference statistically (*P*\<0.05).

AREG; mRNA values of AREG in tumour sections were analysed.
